Imianitov E N, Chernitsa O I, Nikiforova I F, Titov K V, Khanson K P, Kniazev P G
Vopr Onkol. 1992;38(6):652-9.
The occurrence of ERBB-2 (HER-2/NEU) oncogene amplification was studied in 203 DNA samples obtained from 175 cancer patients. Amplification of ERBB-2 oncogene was established in 14 out of 63 (22%) patients with breast cancer, 1 out of 23 cases of ovarian tumor, 1 out of 19 cases of large bowel cancer and 1 out of 27 patients with cancer of the thyroid. Patients with lung cancer (34), soft tissue sarcoma (6) and malignant melanoma (3) failed to reveal any changes in the above oncogene. A tendency was established for ERBB-2 oncogene amplification to be associated with lymph node involvement in female patients with breast cancer: amplification was observed in 9 out of 28 patients presenting with lymph node metastases and only in 5 out of 29 metastases-free cases. To summarize, ERBB-2 oncogene is fairly often activated in human tumors but a high occurrence of the gene amplification was observed in female patients with breast cancer only.
对从175例癌症患者获取的203份DNA样本进行了ERBB - 2（HER - 2/NEU）癌基因扩增情况的研究。在63例乳腺癌患者中有14例（22%）检测到ERBB - 2癌基因扩增，23例卵巢肿瘤患者中有1例，19例大肠癌患者中有1例，27例甲状腺癌患者中有1例。肺癌患者（34例）、软组织肉瘤患者（6例）和恶性黑色素瘤患者（3例）未发现上述癌基因有任何变化。已证实ERBB - 2癌基因扩增与女性乳腺癌患者的淋巴结受累有关：28例有淋巴结转移的患者中有9例检测到扩增，而29例无转移的患者中仅有5例检测到扩增。总之，ERBB - 2癌基因在人类肿瘤中相当常见，但仅在女性乳腺癌患者中观察到该基因的高扩增发生率。
